Analysts Set Eupraxia Pharmaceuticals Inc. PT at $14.33

Eupraxia Pharmaceuticals receives 'Buy' rating from seven brokerages covering the company.

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has received an average rating of 'Buy' from seven brokerages currently covering the company, with one analyst issuing a 'Sell' recommendation, four assigning a 'Buy' rating, and two giving a 'Strong Buy' recommendation. The average 12-month price target among the analysts is $14.33.

Why it matters

The positive analyst sentiment and price target for Eupraxia Pharmaceuticals suggests that the market sees significant potential in the company's clinical-stage pipeline of novel therapies for autoimmune and inflammatory diseases. As a clinical-stage biotech, analyst coverage and ratings are important signals for investors assessing the company's prospects.

The details

Several recent analyst actions have impacted the outlook for Eupraxia Pharmaceuticals. Lifesci Capital raised its rating to 'Strong Buy', while Cantor Fitzgerald increased its price target from $11 to $19 and maintained an 'Overweight' rating. HC Wainwright reaffirmed a 'Buy' rating with a $12 price target, and Leede Financial also upgraded the stock to 'Strong Buy'. However, Wall Street Zen moved its rating from 'Sell' to 'Hold'.

  • Lifesci Capital raised its rating on December 11, 2025.
  • Cantor Fitzgerald increased its price target on January 15, 2026.
  • HC Wainwright reaffirmed its rating on January 9, 2026.
  • Leede Financial upgraded the stock on October 29, 2025.
  • Wall Street Zen moved its rating on December 13, 2025.

The players

Eupraxia Pharmaceuticals Inc.

A clinical-stage biotechnology company dedicated to developing novel therapies for autoimmune and inflammatory diseases.

Lifesci Capital

An equity research firm that raised its rating on Eupraxia Pharmaceuticals to 'Strong Buy'.

Cantor Fitzgerald

An investment bank that increased its price target for Eupraxia Pharmaceuticals and maintained an 'Overweight' rating.

HC Wainwright

A research firm that reaffirmed its 'Buy' rating and $12 price target for Eupraxia Pharmaceuticals.

Leede Financial

A financial services firm that upgraded Eupraxia Pharmaceuticals to a 'Strong Buy' rating.

Wall Street Zen

A research firm that moved its rating on Eupraxia Pharmaceuticals from 'Sell' to 'Hold'.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The positive analyst sentiment and price targets for Eupraxia Pharmaceuticals suggest the market sees significant potential in the company's clinical pipeline, underscoring the importance of analyst coverage and ratings for investors assessing the prospects of clinical-stage biotech firms.